Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972957 | 0.94 | GLP1R (0.62) | GLP1R | |
| SCHEMBL29973096 | 0.93 | GLP1R (0.60) | GLP1R | |
| Sovatelitide SCHEMBL26929010 | 0.90 | GLP1R (0.63) | GLP1R | |
| SCHEMBL30524411 | 0.88 | GLP1R (0.59) | GLP1R | |
| SCHEMBL30423068 | 0.88 | GLP1R (0.59) | GLP1R | |
| SCHEMBL29973649 | 0.87 | GLP1R (0.61) | GLP1R | |
| SCHEMBL29973282 | 0.86 | EDNRA (0.56) | GLP1R | |
| SCHEMBL30533189 | 0.86 | EDNRA (0.73) | GLP1R | |
| SCHEMBL30533188 | 0.85 | EDNRA (0.73) | GLP1R | |
| SCHEMBL31490962 | 0.85 | GLP1R (0.60) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | MIDWESTERN UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| US-20260130858-A1 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | PHARMAZZ INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4734967-A2 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | Pharmazz, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4713094-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS | Pharmazz, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4702986-A1 | POLYPEPTIDE AND USE THEREOF | Biocells (Beijing) Biotech Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4642536-A2 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | Pharmazz, Inc. (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250325636-A1 | USE OF ENDOTHELIN RECEPTOR TYPE B AGONISTS FOR THE TREATMENT OF AORTIC VALVE STENOSIS | INST NAT SANTE RECH MED (FR) | 2025-10-23 | — | — | US | claimed |
| EP-4536198-A1 | USE OF ENDOTHELIN RECEPTOR TYPE B AGONISTS FOR THE TREATMENT OF AORTIC VALVE STENOSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-16 | — | — | EP | claimed |
| US-20250000934-A1 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND METHOD FOR PREPARATION THEREOF | PHARMAZZ, INC. | 2025-01-02 | — | — | US | claimed |
| US-20240382461-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS | PHARMAZZ, INC. (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| WO-2024145197-A2 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | PHARMAZZ, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| US-20240207356-A1 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | PHARMAZZ, INC. (US) | 2024-06-27 | — | — | US | claimed |
| EP-4364811-A2 | ALTERATIONS IN ENDOTHELIN RECEPTORS FOLLOWING HEMORRHAGE AND RESUSCITATION BY CENTHAQUIN | Midwestern University (US) | 2024-05-08 | — | — | EP | claimed |
| EP-3813942-B1 | COMPOSITION COMPRISING CENTHAQUIN OR A SALT THEREOF FOR USE IN TREATING AN INDIVIDUAL SUFFERING ACUTE KIDNEY FUNCTION DECLINE | UNIV MIDWESTERN (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2024057296-A2 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | PHARMAZZ, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| WO-2023237661-A1 | USE OF ENDOTHELIN RECEPTOR TYPE B AGONISTS FOR THE TREATMENT OF AORTIC VALVE STENOSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2023-12-14 | — | — | WO | claimed |
| US-20230172610-A1 | COMBINATORIAL THERAPIES INCLUDING IMPLANTABLE DAMPING DEVICES AND BIOLOGIC THERAPEUTIC AGENTS FOR TREATING A CONDITION AND ASSOCIATED SYSTEMS AND METHODS OF USE | The Brain Protection Company PTY LTD (AU) | 2023-06-08 | — | — | US | claimed |
| CN-115942907-A | Combination therapy including implantable damping devices and biologic therapeutic agents for treating conditions and related systems and methods of use | 卡内基风险投资有限公司 | 2023-04-07 | — | — | CN | claimed |
| EP-4125635-A1 | COMBINATORIAL THERAPIES INCLUDING IMPLANTABLE DAMPING DEVICES AND BIOLOGIC THERAPEUTIC AGENTS FOR TREATING A CONDITION AND ASSOCIATED SYSTEMS AND METHODS OF USE | Carnegie Venture Capital Pty Limited (AU) | 2023-02-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | EDNRB, ADRA2B, ADRB2 | GLP1R 931/4885 |
| US-20260130858-A1 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | SLC5A11, AQP4, SORD | GLP1R 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.